Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.

Eli Lilly & Co. is tapping the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

An international clinical trial aimed at preventing Alzheimer’s disease (AD) in young adults who are at risk of developing ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

University of Pittsburgh, and National Institutes of Health researchers shared promising results on a groundbreaking antibody ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...